Terns Pharmaceuticals stockholders elect three Class II directors, ratify E&Y as auditor

Terns Pharmaceuticals, Inc.

David Fellows, Jill Quigley, and Radhika Tripuraneni elected as Class II directors with 39.5M, 40.1M, and 45.9M votes for, respectively.
Ratification of Ernst & Young as independent auditor for FY 2023 passed with 53.4M votes for, 1,549 against, 331 abstentions.
All director nominees received more votes for than withheld; broker non-votes of 7.4M shares on director election.
No other business items were presented; all proposals were approved as described in the April 28 proxy statement.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Terns Pharmaceuticals, Inc. shareholders approved Ratification of selection of Ernst & Young LLP as independent registered public accounting firm for fiscal year 2023 at the 2023-06-12 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2023-06-12

Exact text from the filing

Proposal 2 . The ratification of the selection, by the audit committee of the board of directors, of Ernst & Young LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2023: Votes For Votes Against Abstentions 53,416,393 1,549 331

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Terns Pharmaceuticals, Inc. shareholders approved Election of three Class II directors to hold office until the 2026 annual meeting at the 2023-06-12 meeting.

Proposal: director election
Outcome: passed
Meeting: 2023-06-12

Exact text from the filing

Proposal 1 . The election of three Class II directors to hold office until the 2026 annual meeting of stockholders or until their respective successor is elected: Nominee Votes For Votes Withheld Broker Non-Votes David Fellows 39,504,333 6,471,007 7,442,933 Jill Quigley, Esq. 40,103,150 5,872,190 7,442,933 Radhika Tripuraneni , M.D., M.P.H. 45,971,176 4,164 7,442,933

View on SEC.gov

224 shareholder votes filed in the last 30 days. Browse all shareholder votes →

Terns Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-027988

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.